Ammonia: more than a neurotoxin? by Rose, Christopher
The final publication is available at http://dx.doi.org/10.1111/liv.12518 
Rose, C.F., 2014. Ammonia: more than a neurotoxin? Liver International, 34(5), p.649-651. 
Editorial 
AMMONIA: MORE THAN A NEUROTOXIN? 
 
Christopher F. Rose 
CRCHUM, Université de Montréal, Montréal, Canada  
 
Ammonia is an inorganic nitrogen compound that is metabolized and produced in all tissues via a number of important 
biochemical reactions. However, a major source of ammonia generation occurs in the gut following protein digestion and 
amino acid deamination. The subsequent ammonia-rich portal blood is effectively removed by the urea cycle in a healthy 
liver, maintaining circulating concentrations of ammonia within 35–65 μM. When liver function is compromized, 
hyperammonaemia arises delivering toxic concentrations of ammonia to the brain, causing deleterious effects. 
Ammonia is composed of a gaseous (NH3) and ionic (NH4
+
) component, where the ratio of NH3/NH4
+
 is a function of pH 
defined by the Henderson–Hasselbach equation. Under normal physiological conditions (pH 7.4) more than 98% of 
ammonia is present as NH4
+
. The ionic properties of NH4
+
 are unique in comparison to other weak bases, as NH4
+
 has a 
comparable ionic radius and diffusion coefficient as potassium (K
+
). Therefore, in addition to ammonia diffusing into cells 
as a gas (NH3), NH4
+
 can cross plasma membranes via K
+
 transporters/channels. 
Elevated levels of ammonia lead to new equilibriums across plasma membranes, which in turn elicit alterations in pH. In 
addition to high ammonia having an effect on cellular metabolism, an increase in NH4
+
 will specifically have an immediate 
impact on the membrane potential. These direct effects of increased ammonia will consequently trigger a cascade of 
pathophysiological events [1]. Although ammonia can disperse and enter all organs throughout the body, it is the brain that 
bears the brunt, as episodes of hyperammonaemia prompt neurological decline. Acquired hyperammonaemia, as observed 
during liver disease/failure, consequently leads to hepatic encephalopathy which includes an array of neuropsychiatric 
abnormalities from cognitive deficits to ataxia, stupor and coma. Inherited hyperammonaemia, as observed in children born 
with genetic defects in the urea cycle, causes neurological posturing, lethargia and seizures. In both cases, ammonia-
lowering strategies remain a primary therapeutic target [2]. 
The study by Jia et al., published in Liver International [3] provides evidence that the toxic effects of ammonia are not 
restricted to the brain, and that elevated concentrations of blood ammonia cause hepatic dysfunction. Jia and colleagues 
demonstrated that increasing blood ammonia levels to concentrations between 120–180 μM for 4 weeks (attained through 
administration of ammonia by gavage twice a day to naïve rats) leads to alterations in liver biochemistry (including 
alanine/aspartate transaminases and total bilirubin) and detection of apoptotic cells in liver (quantified by number of 
TUNEL-positive cells). Histological analysis revealed no cell degeneration or regeneration, no cell necrosis and no 
inflammatory infiltration, however, oedematous hepatocytes were noted. The concept that hyperammonaemia, commonly 
arising under conditions when the liver's capacity to remove ammonia is reduced causes hepatic damage and hepatocyte 
apoptosis is paradoxical. For centuries, the liver has been defined as a vital organ for regulating and detoxifying ammonia. 
Whether ammonia can inadvertently affect the liver, it's primary source of detoxification, and hence perpetuate a vicious 
cycle is captivating and further studies are warranted to clarify this dispute. 
The conclusions by Jia et al., stipulating hyperammonaemia impairs the liver leading to hepatic damage and hepatocyte 
apoptosis is intriguing, as to date there is little compelling evidence supporting this observation. In studies involving 
ammonia and different in vivo and in vitro model systems of the liver, hepatocyte cell death was rarely reported [4]. 
Furthermore, children with inborn errors of the urea cycle infrequently present with hepatocyte apoptosis. Conversely, mild 
hepatic fibrosis, glycogen accumulation and hepatocyte swelling have been found in these young patients, which are 
assumed to be related to age as the progression to these liver abnormalities is slow [5]. Moreover, these pathological 
findings are believed to be related to the type of urea cycle disorder (specific gene defect) and the accumulation of 
respective urea cycle intermediates. Further evidence describing ammonia does not impact on liver function, comes from 
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our group, where we recently demonstrated that by preventing the development of hyperammonaemia in bile-duct ligated-
induced cirrhotic rats with AST-120 (carbon microspheres), the degree of liver damage was not alleviated [6]. In addition, 
Jover and colleagues elegantly demonstrated that inducing hyperammonaemia by feeding naïve rats with a high ammonia 
diet did not result in alterations in liver biochemistry [7]. Also, congenital portal-systemic shunting-induced 
hyperammonaemia does not result in liver damage [8, 9] and moreover rats with portacaval anastomosis (100% portal-
systemic shunting) causing hyperammonaemia and encephalopathy, do not develop hepatic failure [10]. However, portal-
systemic shunting does lead to reduction in liver mass and functional capacity [11, 12]. Nevertheless, this is believed to 
occur as a result of a decrease in liver perfusion (associated with degree of portal systemic shunting) [13] and not ammonia 
toxicity. Taken together, these studies strongly suggest that high ammonia does not impact on liver function and incur 
damage. 
After revealing hepatocyte apoptosis befalls in this ammonia-toxicity rat model, it would have been of utmost value to probe 
for the detection of apoptotic cells in the brains of these same animals. This would have provided insights, in this model, on 
whether the brain and liver react similarly following the ammonia administrations. The underlying reason(s) why ammonia 
is particularly toxic to the brain, or why the brain is more susceptible to ammonia toxicity in comparison to other organs, 
remains incompletely understood. However, knowing the brain accounts for less than 2% of a person's weight but consumes 
20% of the body's energy, these high energy requirements render the brain particularly susceptible to alterations in energy 
metabolism. It has been shown that neurotoxic concentrations of ammonia in the brain lead to alterations in the TCA cycle 
(affecting α-ketoglutarate dehydrogenase activity) [14] but neuronal apoptosis is seldomly reported. 
In fact, historically, hepatic encephalopathy has always been considered to be a reversible metabolic disorder and therefore 
is expected to completely resolve following liver transplantation. However, even following the implantation of a new liver, 
persisting neurological complications remain a common problem affecting as many as 47% (8–47%) of liver transplant 
recipients [15, 16]. Consequently, these enduring neurological complications post-liver transplantation continue to weigh 
severely on the patients’ quality of life, and also lead to longer stays in the hospital causing further financial burden on 
healthcare systems [17]. As a result, the reversibility of hepatic encephalopathy is questioned [18]. Given the success rate of 
liver transplantation is close to 90%, this surgery is no longer considered an experimental high-risk procedure, and thus the 
focus on patient survival has now shifted towards quality of outcome, including neurological status. These incidences of 
neurological impairment following liver transplantation underscore the need for careful neurological assessment in patients 
with liver disease/failure. It is understood that hyperammonaemia plays a primary role in hepatic encephalopathy and it has 
been demonstrated that under certain pathological conditions during liver disease, neuronal cell death ensues [19]. The 
precise role of ammonia and the implications of neuronal cell death in the pathogenesis of hepatic encephalopathy as well as 
in the persisting neurological complications following liver transplantation merits to be further explored. 
In addition to impinging on the brain (and the liver as demonstrated by Jia et al.,), ammonia toxicity has also been shown to 
be implicated in respiratory diseases [20], to cause an upregulation of myostatin [21] and to trigger gastric epithelial cell 
death [22]. Understanding that increased ammonia affects metabolism and physiology in all cells, it is not astonishing that 
ammonia toxicity can impact on all organs. In fact, patients with liver disease regularly develop multi organ failure which 
leads to poor prognosis. Therefore, hyperammonaemia and the involvement of ammonia toxicity in the pathogenesis of 
extrahepatic organ dysfunction (including apoptotic cell death) remains poorly studied and warrants to be investigated. 
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